NOVO-B Stock Analysis: Novo Nordisk | CO
Drug Manufacturers - General | CO, Denmark | Market Cap: 1.097.051m DKK | 12M Return: -29.6% | DK0062498333 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.42B
EPS Trend: 85.3%
Qual. Beats: 2
Rev. Trend: 96.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark, with a large market capitalization of approximately $168 billion. The company operates through two primary segments: Obesity and Diabetes Care, and Rare Disease. Its portfolio includes diabetes and obesity treatments such as GLP-1 receptor agonist therapies like Wegovy, as well as smart insulin pens (NovoPen 6 and NovoPen Echo Plus), growth hormone pens, and hormone replacement therapy products. Beyond its core products, Novo Nordisk maintains a global commercial footprint spanning Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa.
The company has pursued strategic collaborations to bolster innovation, including a partnership with Anthropic to apply artificial intelligence in drug discovery and software development, and an agreement with Orbis Medicines to develop oral macrocycle therapeutics for cardiometabolic diseases. As a major player in the biotechnology sub-industry within the global health care sector, Novo Nordisk is a leading producer of insulin and GLP-1-based therapies, which represent a rapidly growing segment of the pharmaceutical market driven by rising rates of diabetes and obesity worldwide.
- Wegovy and Ozempic sales surge fuel obesity segment growth
- Eli Lillys Zepbound intensifies GLP-1 market competition
- US Medicare drug price negotiations threaten pricing power
| Net Income: 116b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -4.63 > 1.0 |
| NWC/Revenue: -9.22% < 20% (prev -14.37%; Δ 5.14% < -1%) |
| CFO/TA 0.22 > 3% & CFO 133b > Net Income 116b |
| Net Debt (104b) to EBITDA (173b): 0.60 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.44b) vs 12m ago -0.25% < -2% |
| Gross Margin: 80.65% > 18% (prev 83.95%; Δ -3.30% > 0.5%) |
| Asset Turnover: 61.17% > 50% (prev 64.70%; Δ -3.53% > 0%) |
| Interest Coverage Ratio: 8.18 > 6 (EBIT TTM 150b / Interest Expense TTM 18.4b) |
| A: -0.05 (Total Current Assets 209b - Total Current Liabilities 239b) / Total Assets 595b |
| B: 0.38 (Retained Earnings 224b / Total Assets 595b) |
| C: 0.28 (EBIT TTM 150b / Avg Total Assets 539b) |
| D: 0.59 (Book Value of Equity 221b / Total Liabilities 374b) |
| Altman-Z'' = 3.39 = A |
| DSRI: 1.20 (Receivables 109b/85.8b, Revenue 329b/312b) |
| GMI: 1.04 (GM 83.95% / 80.65%) |
| AQI: 0.90 (AQ_t 0.26 / AQ_t-1 0.29) |
| SGI: 1.06 (Revenue 329b / 312b) |
| TATA: -0.03 (NI 116b - CFO 133b) / TA 595b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at DKK 255.25 with a total of 5,041,888 shares traded. Over the past week, the price has changed by +2.61%, over one month by -11.65%, over three months by -19.26% and over the past year by -29.55%.
Current recommended Stop Loss: 238.90 (which is 6.4% or 2.3 ATR below the current price).
Novo Nordisk has no consensus analysts rating.
P/E Trailing = 9.4828
P/E Forward = 12.0048
P/S = 3.3301
P/B = 5.035
P/EG = 4.3787
Revenue TTM = 329b DKK
EBIT TTM = 150b DKK
EBITDA TTM = 173b DKK
Long Term Debt = 122b DKK (from longTermDebt, last quarter)
Short Term Debt = 18.3b DKK (from shortTermDebt, last quarter)
Debt = 149b DKK (from shortLongTermDebtTotal, last quarter) + Leases 8.57b
Net Debt = 104b DKK (calculated: Debt 149b - CCE 45.0b)
Enterprise Value = 1201b DKK (1097b + Debt 149b - CCE 45.0b)
Interest Coverage Ratio = 8.18 (Ebit TTM 150b / Interest Expense TTM 18.4b)
EV/FCF = 24.55x (Enterprise Value 1201b / FCF TTM 48.9b)
FCF Yield = 4.07% (FCF TTM 48.9b / Enterprise Value 1201b)
FCF Margin = 14.85% (FCF TTM 48.9b / Revenue TTM 329b)
Net Margin = 35.35% (Net Income TTM 116b / Revenue TTM 329b)
Gross Margin = 80.65% ((Revenue TTM 329b - Cost of Revenue TTM 63.8b) / Revenue TTM)
Gross Margin QoQ = 78.21% (prev 85.96%)
Tobins Q-Ratio = 2.02 (Enterprise Value 1201b / Total Assets 595b)
Interest Expense / Debt = 12.36% (Interest Expense 18.4b / Debt 149b)
Taxrate = 21.72% (32.3b / 149b)
NOPAT = 118b (EBIT 150b * (1 - 21.72%))
Current Ratio = 0.87 (Total Current Assets 209b / Total Current Liabilities 239b)
Debt / Equity = 0.67 (Debt 149b / totalStockholderEquity, last quarter 221b)
Debt / EBITDA = 0.60 (Net Debt 104b / EBITDA 173b)
Debt / FCF = 2.12 (Net Debt 104b / FCF TTM 48.9b)
Total Stockholder Equity = 197b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.62% (Net Income 116b / Total Assets 595b)
RoE = 59.09% (Net Income TTM 116b / Total Stockholder Equity 197b)
RoCE = 47.16% (EBIT 150b / Capital Employed (Equity 197b + L.T.Debt 122b))
RoIC = 32.91% (NOPAT 118b / Invested Capital 358b)
WACC = 7.87% (E(1097b)/V(1246b) * Re(7.62%) + D(149b)/V(1246b) * Rd(12.36%) * (1-Tc(0.22)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.98 | Cagr: -0.35%
[DCF] Terminal Value 73.10% ; FCFF base≈54.1b ; Y1≈47.5b ; Y5≈38.4b
[DCF] Fair Price = 153.3 (EV 616b - Net Debt 104b = Equity 512b / Shares 3.34b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 85.33 | EPS CAGR: 11.71% | SUE: 2.09 | # QB: 2
Revenue Correlation: 96.08 | Revenue CAGR: 16.54% | SUE: 0.76 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.95 | Chg30d=-0.94% | Revisions=-17% | Analysts=5
EPS current Year (2026-12-31): EPS=21.68 | Chg30d=+1.29% | Revisions=+50% | GrowthEPS=-5.9% | GrowthRev=-2.8%
EPS next Year (2027-12-31): EPS=21.89 | Chg30d=+0.22% | Revisions=-18% | GrowthEPS=+1.0% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: +10% (up=10, down=8)